Antiinflammatory lanostane triterpenoids from Ganoderma lucidum.

Area of Science:

• Natural Product Chemistry
• Pharmacology
• Immunology

Background:

• Ganoderma lucidum (Polyporaceae) is a medicinal mushroom with a history of use in traditional medicine.
• Triterpenoids are a class of compounds found in Ganoderma lucidum, known for various biological activities.
• Cancer chemoprevention is a critical area of research for developing new therapeutic strategies.

Purpose of the Study:

• To isolate and characterize novel and known compounds from Ganoderma lucidum.
• To evaluate the cancer chemopreventive potential of these compounds.
• To investigate their mechanism of action by assessing nitric oxide (NO) production inhibition.

Main Methods:

• Phytochemical analysis of methanolic extracts from Ganoderma lucidum.
• Structure elucidation of a new lanostane triterpenoid using HREIMS, 1D and 2D NMR.
• In vitro evaluation of compounds' ability to inhibit nitric oxide (NO) production in lipopolysaccharide (LPS)-stimulated mouse macrophage RAW 264.7 cells.

Main Results:

• A new lanostane triterpenoid, ganosidone A (1), was identified and isolated, along with eight known derivatives (2-9).
• Compounds 4 and 7 demonstrated significant inhibition of NO production at 50 μM, with inhibition rates of 86.5% and 88.2%, respectively.
• These results suggest a potential role for these compounds in modulating inflammatory responses relevant to cancer chemoprevention.

Conclusions:

• Ganoderma lucidum is a valuable source of bioactive compounds with potential chemopreventive properties.
• Ganosidone A and its derivatives warrant further investigation for their therapeutic applications in cancer prevention.
• The inhibition of nitric oxide production is a key mechanism by which these compounds may exert their chemopreventive effects.